WallStreetZenWallStreetZen

NASDAQ: CERE
Cerevel Therapeutics Holdings Inc Stock

$41.85+0.38 (+0.92%)
Updated Jun 18, 2024
CERE Price
$41.85
Fair Value Price
$3.15
Market Cap
$7.62B
52 Week Low
$19.59
52 Week High
$43.59
P/E
-15.33x
P/B
13.51x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$460.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1
Operating Cash Flow
-$367M
Beta
1.14
Next Earnings
Jul 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CERE Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CERE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CERE ($41.85) is overvalued by 1,229.33% relative to our estimate of its Fair Value price of $3.15 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CERE ($41.85) is not significantly undervalued (1,229.33%) relative to our estimate of its Fair Value price of $3.15 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CERE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CERE due diligence checks available for Premium users.

Be the first to know about important CERE news, forecast changes, insider trades & much more!

CERE News

Valuation

CERE fair value

Fair Value of CERE stock based on Discounted Cash Flow (DCF)
Price
$41.85
Fair Value
$3.15
Overvalued by
1,229.33%
CERE ($41.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CERE ($41.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CERE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CERE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-15.33x
Industry
-7.59x
Market
31.44x

CERE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
13.51x
Industry
6.12x
CERE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CERE's financial health

Profit margin

Revenue
$0.0
Net Income
-$131.9M
Profit Margin
0%
CERE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$1.1B
Liabilities
$562.9M
Debt to equity
1
CERE's short-term assets ($859.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CERE's short-term assets ($859.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CERE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$119.7M
Investing
$19.2M
Financing
$4.5M
CERE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CERE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CERE$7.62B+0.92%-15.33x13.51x
PCVX$7.86B+0.51%-16.88x3.96x
LEGN$7.36B-2.46%-15.69x6.33x
ROIV$8.01B+1.12%1.95x1.34x
ASND$7.17B-1.12%-12.92x-28.01x

Cerevel Therapeutics Holdings Stock FAQ

What is Cerevel Therapeutics Holdings's quote symbol?

(NASDAQ: CERE) Cerevel Therapeutics Holdings trades on the NASDAQ under the ticker symbol CERE. Cerevel Therapeutics Holdings stock quotes can also be displayed as NASDAQ: CERE.

If you're new to stock investing, here's how to buy Cerevel Therapeutics Holdings stock.

What is the 52 week high and low for Cerevel Therapeutics Holdings (NASDAQ: CERE)?

(NASDAQ: CERE) Cerevel Therapeutics Holdings's 52-week high was $43.59, and its 52-week low was $19.59. It is currently -3.99% from its 52-week high and 113.63% from its 52-week low.

How much is Cerevel Therapeutics Holdings stock worth today?

(NASDAQ: CERE) Cerevel Therapeutics Holdings currently has 182,194,722 outstanding shares. With Cerevel Therapeutics Holdings stock trading at $41.85 per share, the total value of Cerevel Therapeutics Holdings stock (market capitalization) is $7.62B.

Cerevel Therapeutics Holdings stock was originally listed at a price of $10.79 in Jun 5, 2020. If you had invested in Cerevel Therapeutics Holdings stock at $10.79, your return over the last 4 years would have been 287.86%, for an annualized return of 40.34% (not including any dividends or dividend reinvestments).

How much is Cerevel Therapeutics Holdings's stock price per share?

(NASDAQ: CERE) Cerevel Therapeutics Holdings stock price per share is $41.85 today (as of Jun 18, 2024).

What is Cerevel Therapeutics Holdings's Market Cap?

(NASDAQ: CERE) Cerevel Therapeutics Holdings's market cap is $7.62B, as of Jun 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cerevel Therapeutics Holdings's market cap is calculated by multiplying CERE's current stock price of $41.85 by CERE's total outstanding shares of 182,194,722.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.